Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Martinez, Pablo ^a   Hernández Losa, Javier ^a   Montero, M Ángeles ^a   Cedrés, Susana ^a   Castellví, Josep ^a   Martinez Marti, Alex ^a   Tallada, Natalia ^a   Murtra Garrell, Nuria ^a   Navarro Mendivill, Alejandro ^a   Rodriguez Freixinos, Victor ^a   Canela, Mercedes ^a   Ramon y Cajal, Santiago ^a   Felip, Enriqueta ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PLATINUM COMPLEX;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PREVALENCE; SMOKING; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84872854915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052261     Document Type: Article

References (24)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ, (2002) Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2: 37.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine 346 (2):: 92-8.
3. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (5676):: 1497-500.
4. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (7153):: 561-6.
5. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, et al. (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clinical Cancer Research 14 (13):: 4275-83.
6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine 363 (18):: 1693-703.
7. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, et al. (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. Journal of Clinical Oncology 27 (26):: 4247-53.
8. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, et al. (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115 (8):: 1723-33.
9. Horn L, Pao W, (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. Journal of Clinical Oncology 27 (26):: 4232-5.
10. Wong K, Koczywas M, Goldman JW, Paschold EH, Horn L, et al. (2011) An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC. Journal of Clinical Oncology 29 (suppl):: abstr 7500.
11. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, et al. (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clinical Cancer Research 16 (22):: 5581-90.
12. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clinical Cancer Research 16 (5):: 1561-71.
13. Yoshida A, Tsuta K, Nitta H, Hatanaka Y, Asamura H, et al. (2011) Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 6 (10):: 1677-86.
14. Kim H, Yoo SB, Choe JY, Paik JH, Xu X, et al. (2011) Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 6 (8):: 1359-66.
15. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine 361 (10):: 958-67.
16. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, et al. (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. American Journal of Pathology 174 (2):: 661-70.
17. Camidge DR, Kono SA, Lu X, Okuyama S, Barón AE, et al. (2011) Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6 (4):: 774-80.
18. Lee JO, Kim TM, Lee SH, Kim DW, Kim S, et al. (2011) Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 6 (9):: 1474-80.
19. Lee JK, Park HS, Kim DW, Kulig K, Kim TM, et al. (2012) Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 118 (14):: 3579-86.
20. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, et al. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12 (11):: 1004-12.
21. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, et al. (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6 (3):: 466-72.
22. Park HS, Lee JK, Kim DW, Kulig K, Kim TM, et al. (2012) Immunohistochemical screening for anaplastic lymphoma Kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77 (2):: 288-92.
23. Mitsudomi T, Tomizawa K, Horio Y, Hida T, Yatabe Y, (2011) Comparison of high sensitivity IHC, FISH, and T-PCR direct sequencing for detection of ALK translocation in lung cancer. Proceedings of the American Society of Clinical Oncology 29 (suppl):: abstr 7534.
24. Tong J, (2011) Immunohistochemical staining for ALK is specific for the detection of ALK-rearranged lung adenocarcinomas. Journal of Thoracic Oncology 6 (S2).